TABLE 2.
Associations between molecular features and response to ICI therapy.
| Feature | Sample size, n | CR/PR, n (%) | SD/PD, n (%) | p Value (χ2 test) | p Value (Fisher exact test) |
|---|---|---|---|---|---|
| All | 89 | 31 (34.8%) | 58 (65.2%) | ||
| PD‐L1 | |||||
| CPS ≥5 | 35 | 17 (48.6%) | 18 (51.4%) | 0.0285 | 0.0403 |
| CPS <5 | 54 | 14 (25.9%) | 40 (74.1%) | ||
| EBV | |||||
| Pos | 6 | 3 (50%) | 3 (50%) | 0.5128 | 0.6637 |
| Neg | 55 | 20 (36.4%) | 35 (63.6%) | ||
| MSI | |||||
| MSI | 7 | 4 (57.1%) | 3 (42.9%) | 0.3354 | 0.4252 |
| MSS | 55 | 21 (38.2%) | 34 (61.8%) | ||
| TMB | |||||
| TMB‐High | 11 | 8 (72.7%) | 3 (27.3%) | 0.0157 | 0.0211 |
| TMB‐Low | 51 | 17 (33.3%) | 34 (66.7%) | ||